Bioamber Inc (NYSE:BIOA) has earned a consensus broker rating score of 2.00 (Buy) from the two analysts that provide coverage for the company, Zacks Investment Research reports. One research analyst has rated the stock with a hold rating and one has given a strong buy rating to the company.

Brokerages have set a 12 month consensus price objective of $6.50 for the company and are forecasting that the company will post ($0.18) earnings per share for the current quarter, according to Zacks. Zacks has also given Bioamber an industry rank of 95 out of 265 based on the ratings given to related companies.

BIOA has been the topic of several research analyst reports. HC Wainwright reaffirmed a “buy” rating and issued a $12.00 price objective on shares of Bioamber in a research report on Wednesday, November 8th. Cowen reaffirmed a “hold” rating and set a $1.00 price objective on shares of Bioamber in a research report on Friday, November 10th. Finally, ValuEngine downgraded Bioamber from a “sell” rating to a “strong sell” rating in a research report on Friday, December 1st.

Shares of Bioamber (NYSE BIOA) remained flat at $$0.37 during trading on Wednesday. 465,750 shares of the company’s stock were exchanged, compared to its average volume of 946,903. The company has a debt-to-equity ratio of 0.24, a current ratio of 1.08 and a quick ratio of 0.75. Bioamber has a fifty-two week low of $0.32 and a fifty-two week high of $6.24.

Institutional investors have recently added to or reduced their stakes in the business. Robecosam AG raised its stake in Bioamber by 82.9% in the third quarter. Robecosam AG now owns 1,478,000 shares of the biotechnology company’s stock valued at $741,000 after buying an additional 670,000 shares during the last quarter. Bank of New York Mellon Corp raised its stake in shares of Bioamber by 336.2% in the second quarter. Bank of New York Mellon Corp now owns 54,106 shares of the biotechnology company’s stock worth $139,000 after purchasing an additional 41,701 shares during the last quarter. FMR LLC raised its stake in shares of Bioamber by 1.9% in the second quarter. FMR LLC now owns 1,360,000 shares of the biotechnology company’s stock worth $3,495,000 after purchasing an additional 25,000 shares during the last quarter. TD Asset Management Inc. purchased a new position in shares of Bioamber in the second quarter worth about $977,000. Finally, Vanguard Group Inc. grew its holdings in Bioamber by 9.9% during the second quarter. Vanguard Group Inc. now owns 303,360 shares of the biotechnology company’s stock worth $780,000 after acquiring an additional 27,278 shares during the period. Institutional investors own 29.97% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This report was first published by American Banking News and is the property of of American Banking News. If you are accessing this report on another site, it was illegally copied and reposted in violation of United States & international copyright & trademark legislation. The correct version of this report can be read at https://www.americanbankingnews.com/2017/12/13/brokerages-set-6-50-price-target-for-bioamber-inc-bioa.html.

Bioamber Company Profile

BioAmber Inc (BioAmber), formerly DNP Green Technology, Inc, is an industrial biotechnology company, which produces sustainable chemicals. The Company’s technology platform combines industrial biotechnology and chemical catalysis to convert renewable feedstocks into sustainable chemicals that are replacements for petroleum-derived chemicals, which are used in a range of everyday products, including plastics, food additives and personal care products.

Get a free copy of the Zacks research report on Bioamber (BIOA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Bioamber Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bioamber and related companies with MarketBeat.com's FREE daily email newsletter.